This site is intended for healthcare professionals only

In association with the Cardiorenal Forum

  • Latest Article

    Growing CONFIDENCE in co-prescribing of SGLT2 inhibitors and non-steroidal MRAs

    Since the findings of the CREDENCE (Canagliflozin and Renal Events in Type 2 Diabetes with Established Nephropathy Clinical Evaluation) were published in 201...

  • Combination finerenone and empagliflozin in CKD with diabetes

  • Acute myocardial infarction management by kidney function across hospitals in England

  • Tolvaptan and the incidence of contrast-induced acute kidney injury

  • The KFRE: does our clinical practice limit its theoretical benefits?

  • Kidney failure risk equation and health inequalities in routine care

  • SOUL: effects of oral semaglutide and cardiovascular outcomes independent of SGLT2 inhibitor use

Show all articles >
alt

For the latest news and articles
Sign up to Renal Review newsletters

Subscribe